From Casetext: Smarter Legal Research

Glaxosmithkline v. Classen Immunotherapies, Inc.

Supreme Court of the United States
Jan 14, 2013
568 U.S. 1137 (2013)

Summary

denying cert.

Summary of this case from Classen Immunotherapies, Inc. v. Biogen Idec

Opinion

No. 11–1078.

2013-01-14

GLAXOSMITHKLINE, petitioner, v. CLASSEN IMMUNOTHERAPIES, INC.


Case below, 659 F.3d 1057.

Petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit denied.

Justice ALITO took no part in the consideration or decision of this petition.


Summaries of

Glaxosmithkline v. Classen Immunotherapies, Inc.

Supreme Court of the United States
Jan 14, 2013
568 U.S. 1137 (2013)

denying cert.

Summary of this case from Classen Immunotherapies, Inc. v. Biogen Idec
Case details for

Glaxosmithkline v. Classen Immunotherapies, Inc.

Case Details

Full title:GLAXOSMITHKLINE, petitioner, v. CLASSEN IMMUNOTHERAPIES, INC.

Court:Supreme Court of the United States

Date published: Jan 14, 2013

Citations

568 U.S. 1137 (2013)
133 S. Ct. 973
184 L. Ed. 2d 751
81 U.S.L.W. 3386

Citing Cases

Classen Immunotherapies, Inc. v. Biogen Idec

On August 31, 2011, the Federal Circuit held that the '139 and '739 patents are eligible for patent…

Classen Immunotherapies, Inc. v. Idec

Classen appealed, and on August 31, 2011, the Federal Circuit reversed, holding that the '139 and '739…